Clinical trials: Metastatic Prostate Adenocarcinoma
Cancer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either…
- Trial name
- NCT04485013
- Testing
- TTX-080, pembrolizumab, cetuximab
- Where
- 41 sites in United States
- Volunteers
- 240 people
- Sponsor
- Tizona Therapeutics, Inc
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
This phase II trial studies how well linsitinib works in treating patients with asymptomatic or mild symptomatic metastatic prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01533246
- Testing
- linsitinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
This phase I/II trial tests the safety, side effects, and best dose of abemaciclib and whether it works before 177Lu-PSMA-617 in treating patients with castration resistant prostate cancer that has spread to other places in the…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- UPLIFT (NCT05113537)
- Testing
- Abemaciclib, Lutetium Lu 177-PSMA-617
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vadim S Koshkin
Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma
A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer
This phase II trial studies the side effects of radiation therapy [hypofractionated proton beam radiation therapy (PBRT) or intensity-modulated radiation therapy (IMRT)] for the treatment of prostate cancer that has come back…
- Conditions
- Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Trial name
- NCT04190446
- Testing
- Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Mayo Clinic
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer, Non-metastatic Prostate Cancer
Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer
Men diagnosed with significant cancer confined to the prostate currently undergo radical therapy directed to the whole prostate (radiotherapy or prostatectomy).
- Conditions
- Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- IP4-CHRONOS (NCT04049747)
- Testing
- Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy], Focal therapy, Focal therapy after Finasteride 5Mg tablets for 12 weeks
- Where
- 10 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Prostate Cancer, Prostate Adenocarcinoma
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
This is a study with the combination of androgen deprivation therapy (ADT) and docetaxel with the addition of enzalutamide in the treatment of subjects with metastatic prostate cancer.
- Trial name
- NCT03246347
- Testing
- ADT+Docetaxel+Enzalutamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Solid Tumor, Advanced Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT06242470
- Testing
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 394 people
- Sponsor
- MacroGenics
Prostate Cancer, Adenocarcinoma of the Prostate
Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01050842
- Testing
- bicalutamide, raloxifene, quality-of-life assessment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer
This phase I trial tests the safety, side effects, best dose and how well giving IL-18 armored STEAP1 CAR T cells after lymphodepleting chemotherapy (with cyclophosphamide and fludarabine) works for the treatment of castration…
- Trial name
- NCT07803653
- Testing
- FH-STEAP1 IL-18 CAR T cells, Antiandrogen Therapy, Biospecimen Collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer
C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer
RATIONALE: New diagnostic procedures, such as C-11 choline PET-CT scan, may be effective in finding cancer that has spread to the bone and lymph nodes in patients with prostate cancer.
- Trial name
- NCT00804245
- Testing
- needle biopsy, PET-CT scans supplemented with 11C-Choline tracer
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors.
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT05960578
- Testing
- Apalutamide, Biopsy, Biospecimen Collection
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Prostate Cancer (Adenocarcinoma)
Multiparametric Whole-Body MRI: a Game Changer in Metastatic Prostate Cancer
WB-MRI is a next-generation imaging technique standardized with the first version of MET-RADs-P guidelines.This narrative review aims to analyse the main scientific evidence available in the literature, explaining what WB MRI is…
- Trial name
- NCT06827340
- Where
- Italy
- Volunteers
- 104 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
This randomized phase III trial studies two different schedules of zoledronic acid to compare how well they work in reducing bone-related complications in patients with breast cancer, prostate cancer, or multiple myeloma that has…
- Conditions
- Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone
- Trial name
- NCT00869206
- Testing
- zoledronic acid
- Where
- 504 sites in United States, Puerto Rico
- Volunteers
- 1,822 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hematological Neoplasms, Non-Hodgkin's Lymphoma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension…
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma
- Trial name
- NCT02223052
- Testing
- CC-486, Vidaza
- Where
- 10 sites in United States
- Volunteers
- 89 people
- Sponsor
- Celgene
Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
- Trial name
- NCT05914116
- Testing
- DB-1311, Lopinavir and Ritonavir Tablets, itraconazole
- Where
- 107 sites in United States, Australia and 2 more
- Volunteers
- 862 people
- Sponsor
- DualityBio Inc.
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05256381
- Testing
- Nanrilkefusp Alfa, Pembrolizumab
- Where
- 54 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- SOTIO Biotech AG
Prostate Cancer, Breast Cancer
Measuring Oncological Value of Exercise and Statin
The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to…
- Conditions
- Prostate Cancer, Breast Cancer, Kidney Cancer, Ovarian Cancer
- Trial name
- MOVES (NCT05796973)
- Testing
- Guided physical exercise, Atorvastatin, Independent exercise
- Where
- Finland
- Volunteers
- 240 people
- Sponsor
- Tampere University Hospital
Prostate Cancer
Flavopiridol in Treating Patients With Recurrent Prostate Cancer
Phase II trial to study the effectiveness of flavopiridol in treating patients with recurrent prostate cancer after hormone therapy.
- Trial name
- NCT00003256
- Testing
- alvocidib
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)